Efficacy of enteral nutrition in patients with Crohn's disease on maintenance anti-TNF-alpha antibody therapy: a meta-analysis

J Gastroenterol. 2020 Feb;55(2):133-141. doi: 10.1007/s00535-019-01634-1. Epub 2019 Oct 22.

Abstract

Enteral nutrition (EN) is effective in Crohn's disease (CD) patients and has been shown to have an inhibitory effect on loss of response to anti-tumor necrosis factor (TNF)-alpha antibody therapy; however, the current level of evidence is not sufficient. The objective of this meta-analysis was to determine whether EN in combination anti-TNF-alpha antibody therapy is useful in maintaining remission. PubMed was used to identify all relevant studies. A total of nine articles were identified including one randomized control trial, two prospective cohort studies, and six retrospective cohort studies. We performed a meta-analysis on all these articles to assess the remission maintenance effect of EN (n = 857). The remission or response maintenance effect in the EN group was 203/288 (70.5%), which was higher than 306/569 (53.8%) in the non-EN group. The odds ratio for long-term remission or response using fixed effects model and random effects model were 2.23 (95% CI 1.60-3.10) and 2.19 (95% CI 1.49-3.22), respectively. The usefulness of EN was unclear in two prospective studies that were conducted immediately after remission induction with anti-TNF-alpha antibody therapy was detected. Differences in the definition of relapse and the observation period among articles were considered to be limitations. This analysis suggests that EN is effective for maintaining remission in patients already in remission or response as a result of anti-TNF-alpha antibody maintenance therapy.

Keywords: Anti-TNF-alpha antibody; Crohn’s disease; Enteral nutrition; Meta-analysis.

Publication types

  • Meta-Analysis
  • Review

MeSH terms

  • Adalimumab / therapeutic use
  • Antibodies, Monoclonal / therapeutic use
  • Certolizumab Pegol / therapeutic use
  • Crohn Disease / therapy*
  • Enteral Nutrition*
  • Humans
  • Infliximab / therapeutic use
  • Maintenance Chemotherapy
  • Tumor Necrosis Factor Inhibitors / therapeutic use*

Substances

  • Antibodies, Monoclonal
  • Tumor Necrosis Factor Inhibitors
  • golimumab
  • Infliximab
  • Adalimumab
  • Certolizumab Pegol